AstraZeneca PLC $AZN Shares Sold by Nwam LLC

Nwam LLC reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 40.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,036 shares of the company’s stock after selling 4,720 shares during the quarter. Nwam LLC’s holdings in AstraZeneca were worth $535,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Goldman Sachs Group Inc. boosted its position in AstraZeneca by 30.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after purchasing an additional 3,224,251 shares during the period. Valeo Financial Advisors LLC lifted its stake in shares of AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after purchasing an additional 2,307,047 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of AstraZeneca by 2,389.9% in the second quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock worth $142,798,000 after buying an additional 1,961,764 shares during the period. American Century Companies Inc. boosted its position in shares of AstraZeneca by 406.9% in the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock worth $148,517,000 after buying an additional 1,621,974 shares during the period. Finally, Jennison Associates LLC grew its stake in shares of AstraZeneca by 15.2% in the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after buying an additional 1,605,133 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 1.6%

NASDAQ:AZN opened at $87.68 on Thursday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The company has a market capitalization of $271.93 billion, a price-to-earnings ratio of 32.96, a price-to-earnings-growth ratio of 1.52 and a beta of 0.34. AstraZeneca PLC has a one year low of $61.24 and a one year high of $89.32. The stock has a 50-day simple moving average of $81.85 and a 200 day simple moving average of $75.95.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same quarter last year, the business posted $2.08 EPS. AstraZeneca’s quarterly revenue was up 12.0% compared to the same quarter last year. Sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AZN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Jefferies Financial Group assumed coverage on AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.